Regeneron Pharmaceuticals, Inc.
STABLE ANTIBODY FORMULATION
Last updated:
Abstract:
The present disclosure provides stable pharmaceutical formulations comprising a human antibody that specifically binds to Ebola Virus (EBOV). In certain embodiments, the formulations contain, in addition to an anti-EBOV antibody, a buffer, an amino acid, a non-ionic surfactant, and a stabilizer. The pharmaceutical formulations of the present disclosure exhibit a substantial degree of antibody stability upon stress, for example, agitation during transport, and storage, for example, storage at temperatures greater than 40.degree. C.
Status:
Application
Type:
Utility
Filling date:
22 Jan 2021
Issue date:
19 Aug 2021